Mandate

VINGE ADVISES NOBINA IN STATE AID COMPLAINT TO THE EUROPEAN COMMISSION

January 20, 2015

Vinge is advising Nobina in a state aid matter where the European Commission has decided to initiate a formal investigation procedure. The matter pertains to potential unlawful state aid to Helsinki Region Transport (Sw. Helsingfors Busstrafik). The Commission’s investigation has been prompted by a complaint from Nobina and relates to several different types of state aid including, inter alia, beneficial loans on terms and conditions and at interest rates which are better than those which are normally available on the financial markets.

Vinge’s team consists of responsible partner Martin Johansson and associate Ina Lunneryd.

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024